NAPANEE, ON, March 11, 2021 /CNW/ - VIVO Cannabis Inc.
(TSX: VIVO) (OTCQX: VVCIF) ("VIVO" or the
"Company") today announced that its Vanluven facility in
Napanee Ontario has received
EU-GMP (European Union Good Manufacturing Practices) certification
from Germany's Brandenburg health
authority, the Landesamt für Arbeitsschutz, Verbraucherschutz und
Gesundheit ("LAVG"). The certification takes effect
immediately and enables VIVO, through its ABcann Medicinals
subsidiary, to export product for sale into European and other
markets requiring products to be manufactured under the rigorous
GMP standards.
At the same time VIVO's German subsidiary Beacon Medical Germany
GmbH received an import licence from the authority to import
medical cannabis flowers from Napanee to Germany and the EU.
VIVO's President of European Operations, Andreas Sander said, "We are very excited about
VIVO's receipt of GMP certification from the German health
authority of the state of Brandenburg. This is a major step forward
in VIVO's commitment to expand our medical cannabis business.
It will allow us to start to provide patients, physicians and
pharmacists with high quality medical cannabis flowers in
Germany, the rest of Europe and beyond. It is a significant
achievement that will help differentiate VIVO from many of its
peers."
VIVO wants to thank the dedication of its GMP team for bringing
this multi-year project to this successful milestone. GMP
certification requires significant resources to achieve and to
maintain. EU-GMP certification will likely provide VIVO the
opportunity to pursue distribution opportunities not only in
Germany but across the EU and in
other global markets in which EU-GMP certification is required for
market access. The Company is now working to achieve the first
European sales of its Beacon Medical™ products, expected by Q3.
About VIVO Cannabis™
VIVO Cannabis™ is recognized for trusted, premium cannabis
products and services. It holds production and sales licences from
Health Canada and operates world-class indoor and seasonal airhouse
cultivation facilities. VIVO has a collection of premium brands,
each targeting different customer segments, including Canna Farms™,
Beacon Medical™, Fireside™, Fireside-X™, Lumina™ and Canadian
Bud Collection™. Harvest Medicine,
VIVO's patient-centric, scalable network of medical cannabis
clinics, has serviced over 150,000 patient visits. VIVO is pursuing
several partnership and product development opportunities and is
focusing its international efforts on Germany and Australia. For more information visit:
vivocannabis.com
Disclaimer for Forward-Looking Information
Certain statements in this news release are, or can be
interpreted as, forward-looking statements, which are statements
that are not purely historical, including statements regarding the
beliefs, plans, expectations or intentions of VIVO and its
management regarding the future. Forward-looking statements in this
news release include that VIVO is expecting to bring its products
to market in Europe, that
physicians, patients and pharmacists will find value in VIVO
products, that GMP certification will provide VIVO the opportunity
to pursue additional international distribution opportunities, that
GMP certification will help VIVO differentiate itself from its
peers, and that it is targeting the first European sales of its
products by Q3 2021.
Such statements are subject to risks and uncertainties that may
cause actual results, performance or developments to differ
materially from those contained in the forward-looking statements,
including: VIVO has not yet shipped product to Germany for sale in that market and may be
unsuccessful doing so; German physcians have not yet prescribed
VIVO products, German pharmacists have not yet dispensed VIVO
products, German patients have not yet taken VIVO products.
The likelihood of these stakeholders interacting with VIVO products
is not yet known; GMP may not provide VIVO with any significant
additional international distribution opportunities; and, VIVO may
fail to achieve the first European sales of its products by Q3
2021.
No assurance can be given that any of the events anticipated by
the forward-looking statements will occur or, if they do occur,
what benefits the Company will obtain from them. Readers are urged
to consider these factors, and the more extensive risk factors
included in the Company's management's discussion and analysis for
the three and nine months ended September
30, 2020, which is available on SEDAR, carefully in
evaluating the forward-looking statements contained in this news
release, and are cautioned not to place undue reliance on such
forward-looking statements, which are qualified in their entirety
by these cautionary statements. The forward-looking statements in
this news release are made as of the date hereof and the Company
disclaims any intent or obligation to update publicly any such
forward-looking statements, whether as a result of new information,
future events or results or otherwise, except as required
SOURCE VIVO Cannabis Inc.